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S U M M A R Y
In a prospective Ibllow-up study of patients with early-onset rheumatoid arthritis, the prevalence of remission according to the 
1981 American Rheumatism Association (ARA) preliminary criteria was evaluated. A total of 227 patients with a median 
follow-up of 3.9 yr and a total of 2832 follow-up visits were studied. The ARA remission criteria were fulfilled in 9.5% of these 
visits. The percentage of patients with at least one visit fulfilling the ARA criteria was for years 2 6 ~ 25%. Each year, 15% 
of the patients were in remission for at least two consecutive visits. A comparison was made between the ARA remission criteria 
and the Disease Activity Score (DAS). DAS <1.6 corresponded with being in remission according to the ARA criteria. The 
DAS is being proposed as a tool to define remission because absence of disease activity should be measured using the same 
method as for higher levels of disease activity, preferably on a continuous scale.
K h y  w o r d s :  Rheumatoid arthritis, Disease Activity Score, Remission.
R h e u m a t o i d  arthritis (RA) is a chronic systemic 
disease o f  unknown aetiology with as its main feature 
polyarthritis leading to joint damage and functional 
impairment. The treatment of RA aims at a reduction 
of disease activity and thereby prevention of joint 
damage and functional impairment. The ultimate goal 
of treatment is remission, i.e. complete suppression of 
sease activity [1,21. The American Rheumatism
(ARA) defined preliminary remission 
criteria [3]. For the development of these criteria, the 
opinion o f  35 rheumatologists about the disease state 
of 344 patients (remission during treatment, remission 
no treatment, partial remission, active disease) was 
chosen as standard. The criteria had to be fulfilled for 
a time period of two consecutive months 
permanent remission cannot be measured in trials, and
in a diehotomous scale: remission yes/no. 
These ARA criteria have been evaluated [4, 5] in two 
studies. In both studies, the patients had an established 
disease; one study was done cross-sectional [5], while in 
the other no standardized follow-up was defined [4], 
The concept of how to measure disease activity has 
changed rather over the last lew years. Core sets of
variables have were based on
consensus o f  several rheumatologists and on the 
validity to measure disease activity [2, 6, 7], It has been
to assess disease activity by these, almost 
ical, core sets, to gain uniformity in 
evaluations of clinical studies. Two out of W I M 4'
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variables mentioned in the ARA criteria o f  remission 
are not included in these core sets, which limits the use 
of these criteria.
Remission, being absence of disease activity, should 
be defined with the same measures as used to assess 
disease activity. We propose the Disease Activity Score 
(DAS), a validated index including only core set 
variables, to assess absence of disease activity [8 
An advantage of defining remission by a continuous 
variable like the DAS is that remission can be placed
¡eh gives thea s ? i * M O activity,
adjust cut-off values o f  DAS with 
respect to new insights.
The goal of this study is to evaluate the prevalence 
of remission according to the ARA preliminary criteria 
in a standardized follow-up study of patients with a 
recent onset of RA. A secondary goal was to 
investigate the relationship of  
criteria with the DAS.
iV* ■<*»**
o
PATIENTS AND M E T H O D S
Patients with reeent-onsel RA visiting 
patient department of the University 
Nijmegen were eligible for this study if they fulfilled the 
following criteria: RA according to the American 
College of Rheumatism criteria (AC'R) [11], a disease 
duration (since diagnosis) of <  1 yr, and not previously
disease-modifying anti-rheumatic drugs 
(DM ARDs). Since 1985 until now, 237 patients look 
part in this study. For different reasons, 10 patients
tret
ire not included: refused participation (/i ~  6) or had 
serious co-morbidities at the time of diagnosis which
-up (// 4, i asia, malignancy, lung
fibrosis). During the follow-up, 15 patients died and 16
(c) 1996 British Society  for R h eu m ato logy
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patients withdrew alive [refusal of follow-up (/? 14)
or moving far away (// 2)].
The patients were seen by research nurses and by one 
of the rheumatologists at least every 3 months. The 
following assessments were made: morning stiffness 
(min); pain on a visual analogue scale of 100 mm (pain; 
0 =  no pain, 100 = worst pain possible); general health
on a visual analogue scale (GI-I; 0 =  best possible,
100 worst possible); erythrocyte sedimentation rate
(ESR) according to Westergren. Also, a complete joint 
examination took place, from which the following joint 
counts (JCs) [12] were calculated: Ritchie Articular 
Index (RA1; 53 joints graded for tenderness); total 
number of tender joints (TOTT; 53 joints); total 
number of swollen joints (TOTS; 44 joints).
Data concerning medication, whether patients had
changed or started with D M A RD s, or
non-steroidal anti-inflammatory drugs (NSAIDs), 
were also collected. Although the treatment schedule 
of the DMARDs has changed slightly during the past 
few years (1985-1993), the following sequence was 
used in most patients: the first step included 
sulphasalazine or hydroxychloroquine, the second step 
methotrexate or i.m. gold, thereafter D-penicillamine 
or azathioprine. Almost all patients were concom­
itantly treated with NSAIDs, and restricted use of 
low-dose corticosteroids as adjuvants was allowed in a 
small number of patients.
The preliminary remission criteria of the ARA [3] are 
described in Table I. The description of the variables, 
however, is not sufficiently detailed. Therefore, the 
following assumptions were made in this study: the 
criterion no joint pain (by history) was replaced by 
the variable pain on a visual analogue scale. To
compensate for inaccuracy, a value of
^  10 mm was chosen to represent no pain; the criterion 
no joint tenderness or pain on motion was fulfilled if 
no joint was scored painful out of 53 
(TOTT =  0); no soft tissue swelling in joints or tendon 
sheaths was fulfilled if no joint was scored swollen out
of 44 joints (TOTS 
morning e
criteria for ESR and 
as mentioned. Fatigue 
was not measured in this study, for this reason we
that 4/5 criteria (instead of 5/6) had to be 
present to qualify for a remission (similar to a part in 
the study of Wolfe and Hawley [4]). Instead of a time 
period of 2 months, we used 3 months in this study.
For each patient, the DAS [8] was calculated by the 
following formula:
DAS 0.54 y R Â Ï  +  0.065 TOTS
+  0.33 In ESR +  0.0072 GFI
The range of the DAS varies from 0 to 10.
In the analyses, only 3-monthly visits were included. 
However, four patients, known by the rheumatologists 
to have low disease activity, refused to visit the 
out-patient department every 3 months. For these 
patients, another follow-up schedule (a minimum of 
one visit a year) was applied. It was assumed that the 
disease activity was low during the period with no
TABLE I
Preliminary ARA remission criteria
Five or more o f  the following criteria must be fulfil led for at least 
two consecutive months:
1. Duration of morning stillness not exceeding 15 min
2. No fatigue
3. No joint pain (by history)
4. No joint tenderness or pain on motion
5. No soft tissue swelling in joints or tendon sheaths
6 . Erythrocyte sedimentation rate (Westergren method) less than 
30 mm after 1 h for a female or 20 mm after 1 h for a male
was
visits, since it was agreed with the patients that in the 
case that complaints recurred they should call for an 
appointment. For these patients, 3-monthly visits were 
added for the period being in remission. For all other 
patients, an interruption of 6 months (one visit missed) 
was allowed. If 
follow-up was ended at that point.
For each patient at each visit, it was calculated how 
many ARA remission criteria were fulfilled. Also, the 
prevalences of the fulfillment of single criteria were 
computed. For each follow-up year (first to sixth), both 
the number of patients in remission and the number of 
visits fulfilling the A R A  remission criteria were 
computed. As a measure of dispersion, medians and 
interquartile ranges (P25-P75) are presented. The 
distribution of DAS values for patients in remission 
and not in remission according to the A RA  criteria is 
presented.
RESULTS
Of the 227 patients included in this study, 63% were 
female; the median age was 55 yr (P25-P75: 43 65 yr), 
78% were IgM rheumatoid factor positive (> 1 0  IU) 
and 53% were FILA-DR4 positive. The 
number of visits of the patients was 13 (P25--P75: 5 22)
and the median duration of follow-up (since diagnosis)
was 3.9 yr (P25-P75: 1.1-5.6 yr).
Of all visits of patients (/? =  2832), the number in 
which five and four o f  the ARA remission criteria were
were, respectively, 72 visits (2.5%) and 198 
visits (7%)). According to this, at 9.5% of all visits 
patients had no disease activity. These visits concern 69 
patients (37%) who fulfilled the criteria at least once 
during follow-up (Table II). The median number of 
‘■remission visits’ per patient was three and ranged from 
1 to 22. -nine patients had at least two 
consecutive visits fulfilling the remission criteria. 
Because of the srence in follow-up duration, 
patients with more visits have more chance of meeting 
the remission criteria. Therefore, the number of 
patients fulfilling the remission criteria per follow-up 
year was calculated. For year 1, the percentage of
patients with at least one remission visit was 10% (6%) 
for two consecutive visits), and for years 2-6 the 
percentage was ~ 2 5 %  (15% for two consecutive 
visits). The relative number of patients who fulfilled the 
remission criteria in a previous year increases with the 
duration of follow-up. However, even at year 6 there 
were patients reaching remission for the first time.
The percentages of all visits (n =  2832) in which a
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TABLE II
The number o f patients in remission according to the A R A  criteria
Patients with 2s 1 'Remission visits’ Patients with i""
Number o f  
patients
'remission visit’ A; *« —* ^  -♦ «  « '« ' wi n • ««*..»4'* Patients with consccutive "remission visits'
Total: Per patient: 'remission visits'
‘•‘Data should be interpreted with caution because o f the variable follow-lip duration.
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follow-up N N % N P50 range in a previous year N %
1 189 18 ( 10) 27 1 [1-3] 11 (6)
2 162 32 (20) 59 1.5 [1- 5] 9 19 ( 12)
3 139 34 (24) 62 2 [1-4] 21 21 (15)
4 112 26 (23) 49 2 [ 1 4 ] 18 15 (13)
5 77 20 (26) 36 1.5(1 4] 15 12 (16)
6 49 15 (31) 37 2 [1 5 ] 13 10 (20)
1 6* 189 69 (37) 270 3 (I 22] j  .* 39 (21)
single criterion of the A RA set was fulfilled was 62% 
for morning stiffness, 22%) for pain, 19%) for
6% for and 65%, for ESR.
Swollen joints seems to be the ‘rate limiter’ for reaching 
remission according to the ARA criteria. Therefore, we 
studied the probability of being in remission according 
to the ARA  if a single criterion is fulfilled or not 
(Table III). The criterion swollen joints most strongly 
determined whether a patient was in remission or not. 
In contrast, the criteria morning stiffness and ESR have 
almost no influence on being in remission or not.
The distribution of DAS for visits that patients did 
or did not fulfil the ARA remission criteria is shown in 
Fig. 1. At a cut-off value for the DAS of  1.6, the 
percentages of misclassification were equal for both 
groups of patients, namely 10%. In Fig. 2, the course 
of the DAS in relation to the ARA criteria is presented 
for four patients. As can be seen in this figure, low DAS 
values correspond with being in remission according to 
the ARA criteria and high DAS values 
in remission. Apart from this, these figures show that 
visits in which patients fulfil the remission criteria are
not
not always consecutive or, if consecutive, only last 
temporarily.
DISCUSSION
As the ultimate goal of treatment of patients with 
RA is achieving a status of complete suppression of 
disease activity, a definition of remission was proposed 
by the ARA preliminary criteria in 1981 [3], However, 
these criteria were only evaluated in two studies [4, 5], 
Both studies included selected patients with established
did not have a standardized follow-up.
p r e v i rIn the present study, 
according to the ARA preliminary criteria in a cohort 
of patients who were followed from the start of the 
disease in a standardized way is described. In addition, 
a comparison was nu 
DAS values as a first attempt to 
criteria consistent with the current views of assessing
In our study, ~  2 5 % of the patients fulfil led at least 
once the A R A  remission criteria, and ~  15% of the
criteria on two consecutive visits. 
In the study of Wolfe and Hawley [4], out of 458 
patients with an established disease with at least three
TABLE III
The impact o f  a single criterion on the state o f remission
Criterion
Single criterion
fulfi
Single criterion
not
M m nim an I iim iM m nw i W M ii i» iiiiir n im i« i n n  t i— > iiip in i rii r  m  mu hi i n  “*i i r n ~ ~ rn ------ r r r n
M orning stillness 
Pain
« *
;r joints 
Swollen joints 
ESR
1 5 %  * 
37% 
46 % 
6 8 %
1 4  %
0  %  
1 %  
0  %  
6 ‘14
1 ‘i/o
*Per cent A R A  remission 'visits’ if  a single criterion is fuUilled/not
fu Hi
clinic visits, 18.1% fulfilled the ARA criteria once. The
results of the study of Alarçon et al. which were
based on only one visit in two populations of different 
countries, showed prevalences of remission of 1 and 
30%, respectively,
criteria. In
patients were selected during a visit at the clinic; 
is in contrast with the present study in which patients
*e from start of
standardized way. Owing to these different selection
strategies i to methodological il is
difficult to compare the different studies.
We had to deal with several problems when upplyi 
the ARA remission criteria in our study. In the first
: criteria are not s
% of moments
remission
no remission
N . /  N
4 5
i
6
« 4# M» Ufc
7
DASvaluea
F ig . I. Comparison o f  DAS values with A R A  pro a IV
remission criteria.
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DAâ-valuea patient 1
check-up
DAS-values *  in rémission ARA
DAS-valuea patient 2
check-up
DAS-values * in rem/aaion ARA
I
DAS-values patient 3
12 14 16 18 20 22 2 4 26 26 30 
check-up
DAS-valuea patient 4
6
1
0  r t T
— .. .  ^  - n  »
a io 12 14 16 16 20 22 24 26 26 30 
check-up
DAS-values * in remission ARA DAS** values * in rémission ARA
Fio. 2. The course o f  thè D A S and thè ARA preliminary remission eriteria in som e individuai patients.
result, several assumptions had to be made to use these 
criteria, also in this study, which will have con­
sequences for the prevalences of remission found. For 
example, the criteria no joint pain and no joint swelling 
were measured by joint counts including 53 and 44 
joints, respectively. If joint counts measuring more 
joints are included in the criteria, a lower prevalence
could be , in of
remission according to the ARA, a time period is also 
included. This aspect, however, could not be invest­
igated in the original study [3] and in the studies of 
Wolfe and Hawley [4] and Alarcon cl al. [5] because 
their follow-up was not standardized. As the frequency 
of follow-up in our study, once in 3 months, did not 
deviate much from the frequency included in the 
definition, we were able to overcome this problem. The 
variable fatigue was not included in our study because 
clinical practice and trial experience showed that ‘time 
until fatigue’ is difficult to assess and, by international 
consensus, fatigue is not included in the core set of 
disease activity variables [2, 7]. Also, no recommenda­
tions on how fatigue is to be measured are given by the 
ARA. Therefore, we modified the criteria so that 4/5 of 
the remaining variables had to be fulfilled.
In the original study of the ARA criteria [3], the 
variable morning stiffness discriminated best. Recently, 
morning stiffness has been evaluated by Hazes cl a'l.
[13]. It appeared that variable was a poor
discriminator between RA and non-inflammatory jo int 
disease, and between active and inactive RA. In the 
present study, this was confirmed because the influence 
of this variable on remission could be neglected: many
s criterion were not in remission. 
In contrast with the variable swollen joints which had 
the largest influence: if it is fulfilled it is, in most cases 
(68%), accompanied by the absence of pain and tender
joints, low ESR and a 
stiffness ( ^  3/4).
of
duration of morning
sease activity in RA has 
undergone quite a change since the proposal of the 
ARA preliminary remission criteria in 1981. At this 
moment, several variables included in the A R A
remission criteria are judged to be less valid and were 
therefore not included in the ACR and EULAR core 
set [6,7]. The DAS is an extensively validated 
composite index which can be calculated with three or 
four variables from the core sets [8-10, 12, 14, 15]. 
Including more variables in the DAS did not increase 
its validity [9]. The DAS, which has a continuous scale, 
corresponds strongly with the ARA preliminary 
remission criteria. This is not surprising as the most 
important elements o f  the A RA  criteria (swollen joints, 
tender joints; Table II) are included in the DAS. At a 
cut-off value of 1.6, the percentages of misclassification
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for patients’ visits in remission or not in remission were 
10%. The problem with a dichotomous variable, 
however, is that a small change in disease activity may 
have a great impact on whether a patient fulfils the 
remission criteria or not. As can be seen in Fig. 2,
during a ‘remission period’ (most o f  the visits in a 
certain time period fulfilled the criteria) at one time 
point a patient does not completely meet the criteria, 
e.g. the follow-up o f  Patients 1 and 4 in Fig. 2.
This study of patients with reeent-onset RA shows 
that remission according to the A R A  criteria seldom 
occurs: the criteria were fulfilled in 9.5% of all visits in 
patients with a median follow-up o f  3.9 yr. During each 
follow-up year wherein the patients were assessed 3
monthly, ~ 2 5 %  of  the patients 
remission criteria once and 15% fulfilled the criteria 
for two consecutive visits. Because complete remission 
cannot easily be assessed, it might be better to use the 
term ‘no disease activity’ instead. No disease activity 
should be measured with the same tools as used to 
assess higher levels of disease activity. The  DAS would 
be preferable because it is a continuous validated index 
using core set variables. DAS levels are in agreement 
with the ARA remission classification. If remission 
should be a dichotomous outcome, this study suggests 
a cut-off point of the DAS of 1.6. F o r  comparison, a 
patient without any swollen or tender joints and an
ESR of 10 mm in l h  has a DAS o f  1.0. Further 
validation of these provisional DAS remission criteria
is needed. It has to be for instance,
whether patients in remission do have less radiographic 
progression and functional loss than patients not in 
remission. In addition, the importance o f  the duration 
of remission should be elaborated further.
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